Drazak" reached revenues of 252 billion tomans in October; domestic sales remain the engine for generating revenues Razak Laboratories' revenues reached approximately 252 billion tomans in October, relying on the sale of domestic pharmaceutical products. However, a comparison between the seven-month performance and the corresponding period last year shows that the company's revenue growth is still accompanied by the challenge of the sales mix and the increase in the cost of supplying raw materials.

Drazak" reached revenues of 252 billion tomans in October; domestic sales remain the engine for generating revenues Razak Laboratories' revenues reached approximately 252 billion tomans in October, relying on the sale of domestic pharmaceutical products. However, a comparison between the seven-month performance and the corresponding period last year shows that the company's revenue growth is still accompanied by the challenge of the sales mix and the increase in the cost of supplying raw materials.